Title: Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells
Authors: Troiani, T ×
Vecchione, Loredana
Martinelli, E
Capasso, A
Costantino, S
Ciuffreda, L P
Morgillo, F
Vitagliano, D
D'Aiuto, E
De Palma, R
Tejpar, Sabine
Van Cutsem, Eric
De Lorenzi, M
Caraglia, M
Berrino, L
Ciardiello, F #
Issue Date: May-2012
Publisher: Harcourt Publishers
Series Title: British Journal of Cancer vol:106 issue:10 pages:1648-1659
Abstract: MEK is activated in ∼40% colorectal cancer (CRC) and 20-30% non-small cell lung cancer (NSCLC). Selumetinib is a selective inhibitor of MEK1/2, which is currently in clinical development.
ISSN: 0007-0920
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Molecular Digestive Oncology (+)
Clinical Digestive Oncology (+)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science